Pre-therapy PSMA PET/CT is a biomarker of target expression that helps to predict patient response to 177Lu-PSMA therapy. ow.ly/TNC850Ih2Vn #PrecisionMedicine #PETCT #ProstateCancer Masatoshi Hotta Jeremie Calais

Patients who do not meet the #PSMA PET/CT eligibility criteria used in the #VISIONtrial and who are treated with #LutetiumPSMA do not respond well to treatment with a PSA50RR of 20%. #Biomarker #prostatecancer #theranostics #PETimaging jnm.snmjournals.org/content/early/…

Not every patient is the same. PET imaging provides whole-body tumor staging and phenotyping information to guide patient selection for cancer treatments Great job #UCLA Nuclear Medicine Team at #ASCO22! @ LoicDjaileb Wesley Armstrong Andrei Gafita Masatoshi Hotta Johannes Czernin

Historic Hat-Trick of Masatoshi Hotta who won the 3rd, 2nd and 1st places best poster awards in the Clinical Oncology category at #SNMMI22 for his work on PSMA PET !! A huge thanks to all the co-authors. #Teamwork #legend #PSMA #theranostics #nuclearmedicine SNMMI UCLA Health

Our research about patients screening for Lu-177 PSMA picked up in a news site. 新しい前立腺癌治療Lu-PSMAに関する我々の研究が紹介されていました。 帰国後は、核医学治療の最新の知見について、日本語で分かりやすく紹介できればと思っています。 cancernetwork.com/view/low-no-ps…

Gave a lecture at the EANM MDD! eanm22.eanm.org/mdd/.... ヨーロッパ核医学会でFAPI PETの非腫瘍性疾患への応用に関して講演しました。FAPは活性化した線維芽細胞に発現するタンパク質で、それをPETで画像化することで、間質性肺炎、心筋梗塞、肝硬変などの評価に役立つ可能性があります。

Oliver Sartor comments on study by Masatoshi Hotta et al (ow.ly/I9Cp50L2Yjn): What is optimal, what is required, what is practical regarding image-based selection for ¹⁷⁷Lu-PSMA patient selection? ow.ly/PhP850L2Yjl #Theranostics = #PrecisionOncology #ProstateCancer

Thank you to all of those that participated in the #RSNA22 Fun Run this morning! We had a total of 441 runners, 676 registrants, and you raised over $29,000! You can contribute to the #RandEFoundation online: bit.ly/3OKR2Ve

LuPSMA coming in for mCRPC patients before chemo ! another major milestone for Nuclear Medicine and theranostics. Congrats Novartis #Theranostics #PSMA #nuclearmedicine #prostatecancer SNMMI JNM novartis.com/news/media-rel…

Peter Maliha provides a rare, illustrated post: A pitfall for FAPi imaging. ow.ly/Ztim50MizWU #NuclearMedicine #MolecularImaging #Cancer #JNuclMed Jeremie Calais

The new PSG score is a PSMA-PET Whole-Body Tumor-to-Salivary Gland Ratio to estimate the target expression at the whole body level using the PET MIP to Predict Response to 177Lu-PSMA (PLUVICTO). Tested by 10 international experts on 237 patients. jnm.snmjournals.org/content/early/…

Newly developed PSG score improves patient selection for PSMA radiopharmaceutical therapy, according to a new study in JNM ow.ly/QTlK50NNRim #NuclearMedicine #RPTherapy #ProstateCancer #JNuclMed

UCLAで行った多施設共同研究が論文化されました。日本でも早くPSMA治療ができるようになることを祈っています。

The #UCLA Nuclear Medicine Clinical Research Team presented 7 abstracts on PSMA-PET/CT at #ASCO23. Little by little, we try to learn and share how to interpret and use the PSMA-PET information for Optimizing Treatment Decision-Making. ascopubs.org/doi/10.1200/AD…

PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study jnm.snmjournals.org/content/64/7/1…

JNM Manuscript of the Month: PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to ¹⁷⁷Lu-PSMA Radioligand Therapy: An International Multicenter Retrospective Study. ow.ly/7kzT50P3Xh2 #NuclearMedicine #ProstateCancer Jeremie Calais Masatoshi Hotta

Breakthrough results from #PSMAfore at #ESMO23: #PLUVICTO Lu177-PSMA617 therapy rPFS = 12 months vs change of AR-inhibitors rPFS = 5.6 months in patients with mCRPC before chemotherapy ! Double !! #theranostics #PSMA Novartis SNMMI oncologypipeline.com/apexonco/esmo-…

#ESMO23 Louise Emmett ANZUP presents: ENZA-P (ANSUP 1901) phase 2 trial results of Enza versus Enza + Lu-177 PSMA-617 in mCRPC #prostatecancer 👉Improved PSA PFS and rPFS with combo👇OncoAlert UroToday.com PCF Science Advanced Prostate Cancer Consensus Conference ESMO - Eur. Oncology

Does FAPI PET uptake reflect pathologic FAP expression in patients with interstitial lung diseases? Spoiler alert: The answer is yes. ow.ly/m8y350TG65j #NuclearMedicine #PETscan #LungDisease Jeremie Calais Masatoshi Hotta Sam Weigt, MD Johannes Czernin

Kinetics of PSMA PET signal after radiotherapy in 217 prostate cancer lesions: It takes multiple months for the uptake to decrease (> 6 months). Beware of "pseudo-progression" on PSMA PET performed shortly after RT. Radiotherapy & Oncology Masatoshi Hotta UCLA sciencedirect.com/science/articl…